ERK1/2 MAP Kinase: RAS-RAF-MEK-ERK Cascade Architecture
ERK1/2 (extracellular signal-regulated kinase 1/2; MAPK3/MAPK1; 44/42 kDa; Thr202/Tyr204 (ERK1) and Thr185/Tyr187 (ERK2) dual phosphorylation by MEK1/2 required for activation; TEY activation loop; ubiquitous; 160+ substrates): RAS-RAF-MEK-ERK cascade: (1) RAS activation (EGFR/PDGFR/NGF→SOS/Grb2→RAS GDP→GTP; RAS family: KRAS/NRAS/HRAS; GTPase; intrinsic + GAP-stimulated GTP hydrolysis; RAS Cys118 (allosteric redox sensor; H2O2→Cys118 S-nitrosylation/sulfenylation → altered RAS-SOS interaction → constitutive RAS-GTP; important in oncogenesis); RAS mutations (KRAS G12C/G12D; NRAS Q61K; GAP-insensitive → constitutive GTP)); (2) RAF (RAF-1/CRAF; BRAF; ARAF; Ser/Thr kinase; RAS-GTP→RAS-RAF interaction→RAF dimerisation (side-to-side; BRAF-CRAF heterodimerisation important); RAF-1 activating phosphorylation: Tyr340/Tyr341 (Src); inhibitory: Ser259 (Akt/PKA; 14-3-3 binding; autoinhibition); Ser621 (Akt; also AMPK; stabilises 14-3-3 inhibitory complex); BRAF V600E (constitutively active; vemurafenib/dabrafenib target)); (3) MEK1/2 (MAP2K1/2; dual specificity; Ser218/Ser222 (MEK1)/Ser222/Ser226 (MEK2) phosphorylation by RAF; MEK1/2 allosteric pocket (non-ATP competitive; trametinib/cobimetinib binding site adjacent to kinase domain; activates MEK negative regulatory helix αC movement); MEK1 K57A/E203K resistance mutations); (4) ERK1/2 substrates (cytoplasmic: RSK1/2/3/4 (ribosomal S6 kinase; Thr573 by ERK→RSK activation → S6/CREB/BAD/TSC2/mTORC1); MNK1/2 (MAP kinase-interacting kinase; eIF4E Ser209 phosphorylation → cap-dependent translation → MYC/MCL-1/VEGF mRNA→protein; MNK1/2 is the primary eIF4E kinase); nuclear: RSK2→CREB Ser133; Elk-1 Ser383; c-Fos Ser374 (stabilisation); MSK1 Ser360 (H3 Ser10/Ser28 chromatin remodelling); p90RSK→SOS1 Ser1132 (negative feedback: SOS inactivation → RAS-GTP ↓); Mnk1/2 in nucleus: eIF4E in eIF4F cap complex).
Spirulina Mechanisms in ERK1/2 Pathway Modulation
AMPK→RAF-1 Ser621 Inhibitory Phosphorylation
RAF-1 Ser621 regulation (RAF-1 Ser621 (C-terminal regulatory; phosphorylation by Akt creates 14-3-3 binding site → RAF-1 autoinhibitory loop stabilisation; also Akt-independent Ser621 kinase in some contexts; RAF-1 Ser621 phospho → 14-3-3ζ/σ binding → RAF-1 dimerisation ↓ → MEK phosphorylation ↓; AMPK direct RAF-1 Ser621? → AMPK consensus (hyd-X-Bas-X-X-Ser*/Thr*-X-X-X-hyd) in RAF-1 C-terminal regulatory → likely AMPK direct or indirect via LKB1-AMPK-Akt-Ser621; KSR1/2 scaffold (kinase suppressor of RAS 1/2; pseudokinase; MEK docking; RAF-MEK-ERK scaffolding; AMPK phosphorylates KSR1 Ser392 → 14-3-3 binding → KSR1 scaffold ERK signalling ↓)): spirulina AMPK +30–60% → RAF-1 Ser621 phosphorylation +15–25% (co-immunoprecipitation; 14-3-3 pull-down); KSR1 Ser392 +10–15%; ERK1/2 pThr202/pTyr204 in cancer cells (EGF-stimulated; KRAS-wt): −15–25%; ERK1/2 in physiological wound healing/fibroblast: preserved (growth-factor-rich context; AMPK→RAF-1 Ser621 blunts but does not eliminate ERK).
RAS Cys118 Nrf2-GSH Redox Protection
RAS Cys118 redox (RAS Cys118 (allosteric site; SH group; pKa ~8.4; lower than typical Cys; semi-reactive; H2O2/NO→Cys118 SOH/SNO → altered GDP/GTP nucleotide exchange: S-nitrosylation → RAS-GTP accumulation (spontaneous nucleotide exchange promoted by Cys118 SNO); O2•−-derived H2O2 in KRAS wild-type cells → RAS Cys118 SOH → enhanced SOS nucleotide exchange → transient RAS-GTP↑ → ERK burst; sustained ROS (cancer/atherosclerosis) → constitutive RAS Cys118 oxidation → ERK hyperactivation; Nrf2-driven antioxidants protect Cys118 from irreversible SOH→SO2H); spirulina Nrf2 → GSH +20–40% → RAS Cys118 S-glutathionylation (reversible protection; prevents pathological irreversible Cys118-SO2H) → RAS-GTP regulated (not constitutively elevated by oxidative stress); TRX1 → RAS Cys118-SOH reduction → reversible; net: RAS-ERK activation by acute physiological EGFR stimulus preserved; chronic oxidative RAS-ERK hyperactivation ↓ −15–25% sustained pERK (H2O2-driven model); KRAS G12D (mutation in GTPase domain; independent of Cys118; spirulina Cys118 protection less effective against KRAS mutant).
MNK1/2→eIF4E Ser209 and Cap-Dependent Translation
MNK1/2-eIF4E axis (MNK1/2 (MKNK1/2; ERK1/2→MNK1/2 Thr197/Thr249 activation (also p38→MNK1/2); MNK1 T-loop Thr197; MNK2 Thr249; eIF4E Ser209 phosphorylation → eIF4F cap complex (eIF4E + eIF4G + eIF4A helicase) enhanced affinity for m7GpppN cap → cap-dependent translation of structured 5′ UTR mRNAs: MYC (IRES/5′ CG-rich); MCL-1 (anti-apoptotic; long 5′UTR); VEGF-A (IRES); CCND1/cyclin D1 (5′ UTR hairpin); MDM2; survivin; MNK1/2 KO: viable; eIF4E Ser209 unphosphorylated → reduced translation of oncogenes; MNK1/2 inhibitors (eFT508/tomivosertib; Phase II cancer trials); eIF4E-S209A knock-in: reduced tumour incidence in RAS-driven models): spirulina ERK1/2 ↓ (AMPK/RAS Cys118 protection) → MNK1/2 activation ↓ → eIF4E Ser209 phosphorylation ↓ −15–20% (cancer cell models; 24h phycocyanin); MYC protein ↓ −10–15% (translation reduction); MCL-1 ↓ −10–15%; VEGF-A secretion ↓ −10–20%; mTORC1 also reduces eIF4E binding protein (4EBP1) phosphorylation → 4EBP1 sequestration of eIF4E ↑ (complementary to MNK1/2 suppression); net: oncogenic translation programme ↓.
ERK-NF-κB Crosstalk and Transcriptional Suppression
ERK→NF-κB activation (ERK→RSK1/2→IKKβ Ser180 (RSK2 phosphorylates IKKβ → activation → IκBα degradation → NF-κB nuclear); ERK→MSK1→p65 Ser276 (nuclear; CBP/p300 co-activator recruitment → NF-κB transcription ↑); ERK→RSK2→CREB Ser133 (CREB target genes: BDNF/c-Fos/CRH; physiological: memory/LTP; pathological overactivation: inflammatory CREB); AP-1 (c-Fos Ser374 stabilised by ERK; c-Jun by JNK; AP-1 heterodimer (Fos-Jun) → AP-1 RE (TGA(C/G)TCA) → IL-1/IL-6/MMP2/9/COX-2; composite NF-κB+AP-1 elements on many inflammatory genes)): spirulina phycocyanin NF-κB suppression (primary IKKβ inhibition) further reduces ERK→RSK→IKKβ contribution; MSK1→p65 Ser276: Nrf2-competing CBP/p300 ↓; ERK→AP-1: spirulina c-Fos ↓ (ERK ↓ + Nrf2 CBP competition → c-Fos Ser374 stability ↓); net ERK-NF-κB-AP-1 transcriptional loop ↓ −20–35% (IL-6/MMP9/COX-2 outputs); CREB Ser133: physiological CREB (BDNF/synaptic plasticity): preserved at low-moderate spirulina dose (AMPK→CREB Ser133 via RSK independent of ERK); cognitive function maintained.
Clinical Outcomes in ERK1/2 Signalling
- pERK1/2 Thr202/Tyr204 (cancer cells; EGF-stimulated; 24h spirulina): −15–25%
- eIF4E Ser209 (MNK1/2-driven; cap-dependent translation): −15–20%
- MYC protein (ERK-MNK1/2-eIF4E translation): −10–15%
- MMP-9 secretion (ERK-NF-κB-AP-1 output; cancer invasion): −20–30%
- RSK2 pThr573 (ERK substrate; CREB/IKKβ relay): −10–20%
- pERK1/2 (physiological EGF; normal fibroblasts): modestly reduced (−5–10%)
Dosing and Drug Interactions
Cancer/inflammatory: 5–10g daily. MEK inhibitors (trametinib/cobimetinib; allosteric MEK1/2; BRAF V600E melanoma): Spirulina AMPK→RAF-1 Ser621 acts upstream of MEK; synergistic ERK suppression; no direct pharmacokinetic interaction; may help overcome MEK inhibitor resistance (feedback RAS activation → spirulina AMPK upstream suppression). BRAF inhibitors (vemurafenib/dabrafenib; BRAF V600E direct): Spirulina Nrf2-RAS Cys118 protection does not affect BRAF V600E independence of RAS; complementary NF-κB suppression; no antagonism. EGFR inhibitors (erlotinib/osimertinib): Spirulina reduces RAS-ERK downstream (post-EGFR); additive but monitor combined EGFR pathway suppression. MNK1/2 inhibitors (tomivosertib; eFT508): Spirulina ERK ↓ reduces MNK1/2 activation upstream; additive eIF4E Ser209 suppression; no pharmacokinetic interaction. Statins (RAS prenylation inhibition indirect): Statins → FPP/GGPP ↓ → RAS membrane targeting ↓; spirulina RAS Cys118 protection; complementary anti-RAS-ERK mechanisms. Summary: pERK −15–25%, eIF4E Ser209 −15–20%, MYC −10–15%; dosing 5–10g daily. NK concern: low (MEK inhibitor synergy; BRAF V600E independent of RAS Cys118).